Lysine methylation of EHMT1/GLP as a molecular switch to reprogram transcription networks in prostate cancer [RNA-seq UNC0642]
Our studies provide novel molecular insights into the activity and function of EHMT1 during PCa progression and suggest a novel therapeutic strategy to treat CRPC with EHMT1 inhibitors. Overall design: LNCaP-tet-EHMT1 cells were treated with/out 0.5ug/mL docxycycline and 2uM UNC0642 for two days. LNCaP cells were treated with siNTC, SiEHMT2 at 20nM for two days. All RNA-seq samples contain replications.